Hepatitis C Policy Project: Latest Hepatitis C News and Research

Latest Hepatitis C News and Research


FDA Approves first 8 week treatment for Hepatitis C Genotype 1-6

The FDA has recently approved Mavyret, a combination of glecaprevir and pribentasvir, for Hepatitis C Genotype 1-6 without cirrhosis. The new drug shortens a previous 12 week treatment to 8 weeks. It is also an additional option for patients who have not been successfully previously.

For more information, see https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm570038.htm

 


17 States have a High HCV rate due to lack of policies to prevent drug users from getting the disease

A report published by the CDC Morbidity and Mortality Weekly Report correlated the lack of policy on injection drug users with an increase incidence of infection of Hepatits C. Most of these States new cases of the disease were attributed to this population but the States lack a tailored policy for this segment of the population.

 

For more information, see  https://hepatitisnewstoday.com/2017/05/18/report-links-high-hepatitis-c-rate-in-17-american-states-to-policy-shortcomings/


Test post of News and latest

 

HELLO THERE!!


test post 2

no text here?


The Stranger Things and Ready Player One trailers are the best

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Curabitur id consectetur metus. Vivamus bibendum mi non facilisis vehicula. Fusce non purus aliquam, mollis enim eu, rhoncus dolor. Ut nec tellus sed justo facilisis venenatis. Praesent vel lorem non diam egestas dapibus.

Duis sagittis, nisi a ultricies aliquet, sem eros tempor ipsum, et sagittis augue dui non tortor. Phasellus efficitur dapibus justo a rhoncus. 606. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Curabitur id consectetur metus. Vivamus bibendum mi non facilisis vehicula. Fusce non purus aliquam, mollis enim eu, rhoncus dolor. Ut nec tellus sed justo facilisis venenatis. Praesent vel lorem non diam egestas dapibus.

Duis sagittis, nisi a ultricies aliquet, sem eros tempor ipsum, et sagittis augue dui non tortor. Phasellus efficitur dapibus justo a rhoncus.